Announcement • Sep 23
Aequus Pharmaceuticals Inc. Appoints Giovanni Di Genova to the Board of Directors, Effective from September 12, 2025 Aequus Pharmaceuticals Inc. announced Giovanni Di Genova has agreed to join the Aequus Board of Directors, subject to the completion of his PIF and TSX approval, effective September 12th, 2025. Aequus is pleased to welcome Giovanni Di Genova as a new director and are eager to work with him on the future ahead. Giovanni Di Genova earned his Bachelor of Science and Bachelor of Pharmacy from McGill University and Universit de Montral, respectively. He began his career in the specialty compounding pharmacy &pharmaceutical industry nearly 35 years ago, covering multiple therapeutic areas including ophthalmology, oncology, gastrointestinal, neurological, infectious, and autoimmune diseases. John has held positions in both innovative and generic pharmaceutical organizations, with roles in API/Materials Management, Production, Sales, Marketing and Business Development. He has a proven track record in strategy and operations, including strong business development experience with M&A, licensing, co-development, and supply agreements. John started his career at Ayerst and PharmaScience, and most recently, served as CEO and founder of Advanced Dosage Forms, a private firm involved in the licensing, sales, marketing, and distribution of high-barrier-to-market niche pharmaceuticals. Announcement • Sep 19
Aequus Pharmaceuticals Inc., Annual General Meeting, Oct 29, 2025 Aequus Pharmaceuticals Inc., Annual General Meeting, Oct 29, 2025. Location: british columbia, vancouver Canada Reported Earnings • Nov 10
Third quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.006 loss in 3Q 2023) Third quarter 2024 results: CA$0.005 loss per share (improved from CA$0.006 loss in 3Q 2023). Revenue: CA$148.3k (up CA$135.0k from 3Q 2023). Net loss: CA$614.7k (loss narrowed 24% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 53% per year, which means it is performing significantly worse than earnings. Reported Earnings • Sep 01
Second quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.005 loss in 2Q 2023) Second quarter 2024 results: CA$0.005 loss per share (in line with 2Q 2023). Revenue: CA$161.4k (up 64% from 2Q 2023). Net loss: CA$683.0k (loss narrowed 2.5% from 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has fallen by 56% per year, which means it is performing significantly worse than earnings. Reported Earnings • May 02
Full year 2023 earnings released: CA$0.022 loss per share (vs CA$0.024 loss in FY 2022) Full year 2023 results: CA$0.022 loss per share (improved from CA$0.024 loss in FY 2022). Revenue: CA$254.9k (down 82% from FY 2022). Net loss: CA$2.96m (loss narrowed 7.6% from FY 2022). New Risk • Dec 01
New major risk - Revenue and earnings growth Earnings have declined by 0.7% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.8m free cash flow). Share price has been highly volatile over the past 3 months (75% average weekly change). Negative equity (-CA$3.6m). Earnings have declined by 0.7% per year over the past 5 years. Revenue is less than US$1m (CA$587k revenue, or US$433k). Market cap is less than US$10m (€2.69m market cap, or US$2.93m). Reported Earnings • Sep 03
Second quarter 2023 earnings released: CA$0.005 loss per share (vs CA$0.006 loss in 2Q 2022) Second quarter 2023 results: CA$0.005 loss per share (improved from CA$0.006 loss in 2Q 2022). Revenue: CA$98.4k (down 72% from 2Q 2022). Net loss: CA$700.9k (loss narrowed 9.2% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings. Announcement • Aug 25
Aequus Pharmaceuticals Inc. Announces Launch of Zimed PF in Canada Aequus Pharmaceuticals Inc. announced the launch of Zimed® PF, the first preservative-free multi-dose Bimatoprost for glaucoma patients in Canada. Announcement • Aug 19
Aequus Pharmaceuticals Inc. Announces Pause in Sales of Evolve Intensive Eyedrop and Intensive Gel Products in Canada Aequus Pharmaceuticals Inc. announced the pause of sales of its Evolve Intensive eyedrop and Intensive gel products in Canada. The manufacturer, Medicom Healthcare (UK), is in the process of changing its MDSAP provider. The switch was necessitated by the existing Notified Body being unable to offer all relevant global certifications. Until this process is completed, Aequus Pharmaceuticals will pause sales of the class leading Evolve® range of products in the Canadian market. The company look forward to Evolve® returning to patients in Canada as soon as MDSAP Certification is issued. Aequus and Medicom Healthcare assure valued customers and eyecare professionals that the Evolve® Intensive eyedrops and gel will return to the Canadian market soon. The Company remains steadfast in its commitment to delivering innovative solutions that enhance the well-being of patients across Canada. Reported Earnings • Jun 02
First quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.007 loss in 1Q 2022) First quarter 2023 results: CA$0.006 loss per share (improved from CA$0.007 loss in 1Q 2022). Revenue: CA$92.3k (down 70% from 1Q 2022). Net loss: CA$744.3k (loss narrowed 19% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings. Announcement • May 27
Aequus Pharmaceuticals Inc., Annual General Meeting, Jul 25, 2023 Aequus Pharmaceuticals Inc., Annual General Meeting, Jul 25, 2023. Reported Earnings • Dec 01
Third quarter 2022 earnings released: CA$0.004 loss per share (vs CA$0.003 loss in 3Q 2021) Third quarter 2022 results: CA$0.004 loss per share (further deteriorated from CA$0.003 loss in 3Q 2021). Revenue: CA$347.9k (down 51% from 3Q 2021). Net loss: CA$500.5k (loss widened 31% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Marc Lustig was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 31
Second quarter 2022 earnings released: CA$0.006 loss per share (vs CA$0.004 loss in 2Q 2021) Second quarter 2022 results: CA$0.006 loss per share (down from CA$0.004 loss in 2Q 2021). Revenue: CA$346.5k (down 47% from 2Q 2021). Net loss: CA$772.1k (loss widened 61% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings. Board Change • Jul 21
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Marc Lustig was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Dec 31
High number of new directors Independent Director Marc Lustig was the last director to join the board, commencing their role in 2021. Reported Earnings • Nov 04
Third quarter 2021 earnings released: CA$0.003 loss per share (vs CA$0.003 loss in 3Q 2020) The company reported a soft third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: CA$712.0k (up 15% from 3Q 2020). Net loss: CA$381.5k (loss widened 52% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Director Overboarding • Sep 02
Director Marc Lustig has joined 5th company board Marc Lustig has been appointed to the board of BriaCell Therapeutics Corp. (TSXV:BCT). Lustig now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations. Director Overboarding • Sep 02
Director Marc Lustig has joined 5th company board Marc Lustig has been appointed to the board of BriaCell Therapeutics Corp. (TSXV:BCT). Lustig now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations. Director Overboarding • Sep 02
Director Marc Lustig has joined 5th company board Marc Lustig has been appointed to the board of BriaCell Therapeutics Corp. (TSXV:BCT). Lustig now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations. Director Overboarding • Sep 02
Director Marc Lustig has joined 5th company board Marc Lustig has been appointed to the board of BriaCell Therapeutics Corp. (TSXV:BCT). Lustig now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations. Reported Earnings • Aug 31
Second quarter 2021 earnings released: CA$0.004 loss per share (vs CA$0.003 loss in 2Q 2020) The company reported a soft second quarter result with increased losses and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: CA$651.5k (up 20% from 2Q 2020). Net loss: CA$479.0k (loss widened 116% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Reported Earnings • Jun 01
First quarter 2021 earnings released: CA$0.005 loss per share (vs CA$0.005 loss in 1Q 2020) The company reported a poor first quarter result with increased losses, weaker revenues and weaker control over costs. First quarter 2021 results: Revenue: CA$491.8k (down 15% from 1Q 2020). Net loss: CA$621.7k (loss widened 53% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Reported Earnings • Apr 25
Full year 2020 earnings released: CA$0.011 loss per share (vs CA$0.039 loss in FY 2019) The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: CA$2.59m (up 59% from FY 2019). Net loss: CA$1.05m (loss narrowed 66% from FY 2019). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Reported Earnings • Dec 01
Third quarter 2020 earnings released: CA$0.003 loss per share The company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: CA$619.0k (up 67% from 3Q 2019). Net loss: CA$251.9k (loss narrowed 62% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.